OLMA
Income statement / Annual
Last year (2023), Olema Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Olema Pharmaceuticals, Inc.'s net income was -$96.66 M.
See Olema Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$377,000.00 |
$1.66 M |
$1.66 M |
$11,000.00 |
$9,033.00 |
$8,244.00 |
| Gross Profit |
-$377,000.00 |
-$1.66 M |
-$1.66 M |
-$11,000.00 |
-$9,033.00 |
-$8,244.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$86.14 M
|
$82.27 M
|
$51.10 M
|
$13.70 M
|
$3.92 M
|
$1.69 M
|
| General & Administrative
Expenses |
$18.82 M
|
$24.71 M
|
$20.39 M
|
$7.82 M
|
$403,000.00
|
$386,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.82 M
|
$24.71 M
|
$20.39 M
|
$7.82 M
|
$403,000.00
|
$386,000.00
|
| Other Expenses |
$0.00 |
-$27,000.00 |
-$47,000.00 |
$0.00 |
$0.00 |
-$31,000.00 |
| Operating Expenses |
$104.96 M |
$106.99 M |
$71.49 M |
$21.53 M |
$4.32 M |
$2.08 M |
| Cost And Expenses |
$104.96 M |
$106.99 M |
$71.49 M |
$21.53 M |
$4.32 M |
$2.08 M |
| Interest Income |
$8.32 M |
$2.23 M |
$442,000.00 |
$60,000.00 |
$7,000.00 |
$4,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$653,000.00 |
$0.00 |
$28,000.00 |
| Depreciation &
Amortization |
$377,000.00
|
$1.66 M
|
$1.66 M
|
$11,000.00
|
$9,033.00
|
$8,244.00
|
| EBITDA |
-$104.58 M
|
-$103.13 M
|
-$69.43 M
|
-$21.52 M
|
-$4.31 M
|
-$2.16 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.31 M
|
$2.20 M
|
$395,000.00
|
-$593,000.00
|
$7,000.00
|
-$118,000.00
|
| Income Before Tax |
-$96.66 M |
-$104.79 M |
-$71.10 M |
-$22.12 M |
-$4.32 M |
-$2.20 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$2.20 M |
-$210,000.00 |
$642,000.00 |
-$155,860.00 |
-$90,000.00 |
| Net Income |
-$96.66 M |
-$102.59 M |
-$70.89 M |
-$22.76 M |
-$4.32 M |
-$2.20 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.14 |
-2.56 |
-1.79 |
-0.58 |
-0.11 |
-0.16 |
| EPS Diluted |
-2.14 |
-2.56 |
-1.79 |
-0.58 |
-0.11 |
-0.16 |
| Weighted Average Shares
Out |
$45.25 M
|
$40.00 M
|
$39.52 M
|
$39.31 M
|
$40.17 M
|
$14.10 M
|
| Weighted Average Shares
Out Diluted |
$45.25 M
|
$40.00 M
|
$39.52 M
|
$39.31 M
|
$40.17 M
|
$14.10 M
|
| Link |
|
|
|
|
|
|
